Authors

Latest:

Future Perspectives in the Treatment of Advanced RCC

Oncologists discuss the need for more data on treatment duration in advanced RCC, emphasize the value of long-term patient follow-ups, and highlight the translational focus of the KCRS annual meeting, which combines clinical and early-stage research for renal cell carcinoma.

Robert J. Soiffer, MD, Dana-Farber Cancer Institute

Robert Korngold, PhD

Latest:

Robert Korngold on Advances in Bone Marrow Transplant

Robert Korngold, PhD, John Theurer Cancer Center looks back on the advances we've made so far in bone marrow transplant.

Robert L. Coleman, MD

Latest:

Dr. Coleman on the FDA Approval of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Robert L. Coleman, MD, FACOG, FACS, discusses the FDA approval of tisotumab vedotin in recurrent or metastatic cervical cancer.

Robert L. Coleman, MD, FACOG, FACS

Latest:

Future Outlook of Advanced Ovarian Cancer Treatment

Comprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.

Robert L. Coleman, MD, FACOG, FACS, The University of Texas MD Anderson Cancer Center

Robert L. Coleman, MD, MD Anderson Cancer Center

Robert L. Ferris, MD, PhD

Latest:

Dr. Ferris on the Safety Profile of Transoral Robotic Surgical Resection in Oropharynx Cancer

Robert L. Ferris, MD, PhD, discusses the safety profile of transoral robotic surgical resection in oropharynx cancer.

Robert L. Ferris, MD, PhD, FACS, University of Pittsburgh Cancer Institute

Robert L. Ferris, MD, PhD, Pittsburgh

Robert L. Ferris, MD, PhD, University of Pittsburgh Cancer Institute

Robert L. Ferris, MD, PhD, UPMC Hillman Cancer Center

Robert L. Fine, MD

Latest:

Dr. Fine on GTX in Inoperable Pancreatic Cancer

Robert L. Fine, MD, an associate professor of Medicine at New York Presbyterian Hospital-Columbia University Medical Center, discusses a phase II study that evaluated the efficacy of neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX) in patients with inoperable pancreatic adenocarcinoma

Robert L. Kirkman, MD

Latest:

Dr. Kirkman on the Novel HER2-Specific Inhibitor ONT-380 for Breast Cancer

Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.

Robert L. Redner, MD

Latest:

Dr. Redner on the Activity of Venetoclax in AML

Robert L. Redner, MD, a medical oncologist and hematologist, and professor of medicine, at the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, discusses the activity of venetoclax (Venclexta) in acute myeloid leukemia (AML).

Robert L. Talley, MD

Latest:

Dr. Talley on Clinical Trials for Patients With Chronic Leukemias

Robert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses clinical trials for patients with chronic leukemias.

Robert Laszewski

Latest:

Robert Laszewski on the Effect of ACA on Urology Practices

Robert Laszewski, President, Health Policy and Strategy Associates, LLC, discusses the effects of the Affordable Care Act (ACA) on urology practices.

Robert Louis Ferris, MD, PhD

Latest:

Dr. Ferris on Combining STING Agonists With Checkpoint Inhibitors in Head and Neck Cancer

Robert L. Ferris, MD, PhD, discusses combining STING agonists with checkpoint inhibitors in head and neck cancer.

Robert M. Jotte, MD, PhD

Latest:

Dr. Jotte on the Low Rate of Screening in Lung Cancer

Robert M. Jotte, MD, PhD, medical director and co-chair of the USON Thoracic Committee at Rocky Mountain Cancer Centers, discusses the low rate of screening for lung cancer.

Robert M. Rifkin, MD

Latest:

Dr Rifkin on the Evaluation of Prophylactic Tocilizumab Prior to Teclistamab in R/R Myeloma

Robert M. Rifkin, MD, FACP, discusses the use of prophylactic tocilizumab to reduce teclistamab-related CRS in relapsed/refractory myeloma.